Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 30.16% | 6.84% | |||
| Gross Profit | -30.16% | -6.84% | |||
| SG&A Expenses | 5.05% | -4.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.60% | 1.60% | |||
| Operating Income | -19.60% | -1.60% | |||
| Income Before Tax | -25.28% | 4.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.11% | 4.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.11% | 4.03% | |||
| EBIT | -19.60% | -1.60% | |||
| EBITDA | -19.68% | -1.64% | |||
| EPS Basic | -24.30% | 18.46% | |||
| Normalized Basic EPS | -6.62% | 4.95% | |||
| EPS Diluted | -24.30% | 18.46% | |||
| Normalized Diluted EPS | -6.62% | 4.95% | |||
| Average Basic Shares Outstanding | 0.66% | 17.69% | |||
| Average Diluted Shares Outstanding | 0.66% | 17.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||